Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program
The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…
